Detection of Recurrent Prostate Cancer With 18F-Fluciclovine PET/MRI

Abstract

Combined ¹⁸F-fluciclovine PET/MRI can detect lesions suspicious for recurrent prostate cancer in patients with a range of PSA levels. Combined PET/MRI may be useful to select patients for appropriate treatment, but is of limited use at low PSA values or in patients classified as EAU Low-Risk BCR, and the clinical value of ¹⁸F-fluciclovine PET/MRI in this study was too low to justify routine clinical use.